openPR Logo
Press release

Global Hyperlipidemia Drug Market Size, Comprehensive Analysis & Forecast to 2025

06-15-2020 02:48 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Orion Market Research

The global hyperlipidemia drug market is estimated to witness significant growth during the forecast period. The demand for a statin to manage cholesterol is driving the market growth across the globe. This drug supports lowering cholesterol, hence reduce the chances of cardiovascular diseases, stroke, and diabetes. Statins are used to manage the plaque on blood vessels and reduce the risk of blood clots. There are various statins options are available in the market for lowering cholesterol levels. Some of the statins used in the US include Atorvastatin (Lipitor), Lovastatin (Altoprev), Pitavastatin (Livalo, Zypitamag), Pravastatin (Pravachol), Rosuvastatin (Crestor, Ezallor), and Simvastatin (Zocor).

Get Free Sample Copy @ https://www.omrglobal.com/request-sample/hyperlipidemia-drug-market

Further, according to the American Heart Association (AHA), historical data shows 79.8% of adults who were at least 40 years old use of statins for lowering cholesterol from 2002 to 2013 studies. Such an extensive rise in the number of statinusers is driving the growth of the hyperlipidemia drug market. However, increasing side effects associated withstatin drugs is expected to hinder the growth of the statin drug market. Statins drugs have side effects and some patients are unable to bear it. For instance, atorvastatin and rosuvastatin are high-intensity statins which cause rare side effects like new-onset diabetes and muscle symptoms.

A Full Report of Global Hyperlipidemia Drug Market is Available at: https://www.omrglobal.com/industry-reports/hyperlipidemia-drug-market

Hence, the demand for non-statin drugs is expected to contribute to hyperlipidemia drug market growth in the near future. In 2020, the FDA has approved two non-statin drugs after a long period of the last 2 decades. For instance, in February 2020, The FDA approved the first non-statin oral medication for high cholesterol commercialized in the US and around the world. The drug, bempedoic acid, is the first in a new class of drugs to treat low-density-lipoprotein cholesterol.

Further, in February 2020, Esperion Therapeutics Inc received FDA approval for its Nexletol, a new type of cholesterol-lowering drug. This drug will help people manage their high cholesterol and reduce the risk of heart diseases. Further, other non-statin drugs for lowering cholesterol include PCSK9-targeting drugs such as Amgen’s Repatha (evolocumab), Sanofi’s Praluent (alirocumab) and inclisiran, developed by Alnylam Pharmaceuticals and The Medicines Company and currently under FDA review.

Global Hyperlipidemia Drug Market Segmentation

By Drug Class

HMG-CoA Reductase Inhibitors (Statins)
PCSK9 Inhibitors
Cholesterol Absorption Inhibitors
Fabric Acid Derivatives (Fibrates)
Niacin (Nicotinic Acid)
Bile Acid Sequestrants (BAS)
Combination Therapy and Compliance
Others

Global Hyperlipidemia Drug Market Segmentation by region

North America

United States
Canada

Europe

UK
Germany
Italy
Spain
France
Rest of Europe

Asia-Pacific

China
Japan
India
Rest of the Asia-Pacific

Rest of the World

Middle East & Africa
Latin America

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/hyperlipidemia-drug-market

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 780-304-0404

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Hyperlipidemia Drug Market Size, Comprehensive Analysis & Forecast to 2025 here

News-ID: 2074689 • Views: 523

More Releases from Orion Market Research

Genotyping Market Trends, Segmentation, Growth, Analysis and Forecast 2023-2029
Genotyping market is expected to grow at a significant rate during the forecast period. The genotyping technologies offer tool set to examine a wide range of genetic variation. The analysis of genetic variation and genomic profiling can be done by a broad range of products such as microarray and DNA sequencer. Genotyping is used to determine the gene variants associated with the disease. Genotyping Market reports provides us with a
Cell Culture Market Share, Trends, Future Outlook, Analysis and Forecast 2023-20 …
The global cell culture market is projected to grow at a significant CAGR of 15.3% during the forecast period. The market is mainly driven by the high application of cell culture systems used in the drug discovery and tissue engineering. Cell culture technology is widely used for the drug development and biosensors. Cell Culture Market reports provides us with a complete outlook on thorough assessment of thorough data about vital
Cancer Tumor Profiling Market Share, Trends, Future Outlook, Analysis and Foreca …
Global cancer/tumor profiling market is anticipated to grow at a CAGR of 8%, during the forecast period. Cancer/tumor profiling offers much-needed information about the genes that cause cancer, which in turn, provides insights regarding the mechanism of cancer. Cancer Tumor Profiling Market reports provides us with a complete outlook on thorough assessment of thorough data about vital feature of the global industry related to market size, revenue, development and market
Bio Electronics Market Share, Trends, Future Outlook, Analysis and Forecast 2023 …
The global bioelectronics market is anticipated to grow at a significant CAGR of 9.7% during the forecast period. Bioelectronics plays a prominent role in the medical device industry owing to the new technologies such as biosensors and nanotechnology that support the expansion of the life science domain. Bio Electronics Market reports provides us with a complete outlook on thorough assessment of thorough data about vital feature of the global industry

All 5 Releases


More Releases for Drug

Alcohol Testing And Drug Testing Equipment Market 2025 Segmentation, Application …
Market Study Report, LLC, has compiled an exhaustive research study of the ‘Alcohol Testing And Drug Testing Equipment market’, detailing every single market driver and intricately analyzing the business vertical. This ‘Alcohol Testing And Drug Testing Equipment market’ study will aid in seeking out new business opportunities and fine-tuning existing marketing strategies through insights regarding SWOT analysis, market valuation, competitive spectrum, regional share, and revenue predictions. Alcohol abuse and drug
How much Diabetes Drug Market Impact Worldwide Medical Drug Industry?
Diabetes Drug Market From an insight perspective, the market report focuses on various levels of analyses — industry analysis, market rank analysis, and company profiles, which together comprise and discuss basic views on the competitive landscape, high-growth regions, and countries as well as their respective regulatory policies, Types ,Applications and opportunities in the market.  Diabetes is a metabolic disorder in which the body glucose level is elevated. There are two types of diabetes
Hepatitis Drug Market Hepatitis Drug Clinical Pipeline Report 2023
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Introduction to Hepatitis Disease 1.1 Prologue 1.1.1 History of Hepatitis 1.1.2 Causes of Hepatitis Disease 1.2 Types of Viruses which are Responsible for Hepatitis Disease 2. Global Prevalence of Hepatitis Infection 3. Available Drug Classes for Hepatitis Disease Treatment 3.1 Interferon Alfa Therapy 3.2 Protease Inhibitors Therapy 3.3 Polymerase
Microcapsules Drug Delivery Market Microcapsules Drug Delivery Sales Report 2022
For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990 Report Table of Contents 1. Indispensable Advent of Microcapsules 1.1 Trajectory of Microencapsulation 1.2 Why and wherefores for Microencapsulation 2. Characterization of Microcapsules 2.1 Composition of Microcapsules 2.2 Parameters Influencing Microcapsules 3. Engineering Technology of Microcapsules 3.1 Physical Manufacturing Technologies 3.2 Physicochemical and Chemical Technologies 4. Applicability of Microcapsules 4.1 Microcapsules in Pharmaceuticals 4.2 Microcapsules in Nutraceuticals
AstraZeneca’s NMOSD Drug receives orphan drug designation
April 18, 2017 Orphan Drug European Medicine Agency has Announced orphan drug designation for inebilizumab (earlier known as MEDI-551) developed by AstraZeneca PLC (AZN) for the treatment of neuromyelitis optica spectrum disorder (NMOSD). The drug has already received orphan drug status from US Food and Drug Administration (FDA). NMOSD, also called Devic’s disease, is a rare, autoimmune disorder of the central nervous system (CNS) that affects the functioning
Drug Discovery Strategies, PBPK Modeling and Drug-Drug Interaction Explored and …
This year’s 12th annual ADMET conference and exhibition promises to deliver appearances from experienced pharmaceutical professionals from ADME and PK/PD organisations such as AbbVie, GSK, Roche and Bayer when it returns to London this June. The carefully selected speaker line up will be addressing early ADME application strategies and discussing the latest technologically advanced screening and testing models along with exploring ADMET technologies which will identify properties of a drug